ArticleMolecular neurodegeneration2025

Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson's disease.

Heeyoung An et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.